23andMe Investor Presentation Deck
23ME'610 Targeting CD200R1: A Genetically-Validated
Approach to Anti-Cancer Therapy
CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway.
• 23ME-00610 is a high-affinity, first-in-class, anti-CD200R1 antibody with immune-activating
properties, including:
O Prevention of CD200-mediated suppression of chronically stimulated T cells
O Enhancement of cytokine secretion from peripheral blood mononuclear cells (PBMCs) isolated
from cancer patients
O o Augmentation of PBMC-mediated tumor cell killing
CD200R1 expression was observed on tumor infiltrating lymphocytes from The Cancer Genome Atlas,
suggesting that this pathway contributes to an immunosuppressive tumor microenvironment.
CD200R1 was also expressed in immune checkpoint inhibitor non-responders, indicating that
inhibition of the CD200R1 immune checkpoint has the potential to address resistance to anti-PD-1 and
anti-CTLA4 therapies¹.
Phase 2a portion of the study study will evaluate five tumor indication-specific expansion cohorts and
a cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies.
1. Data presented in poster at 2022 American Association for Cancer Research (AACR) annual meeting.View entire presentation